Online inquiry

IVTScrip™ mRNA-Anti-S, CB-6(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5258MR)

This product GTTS-WQ5258MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, CB-6(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ5258MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1077MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-838
GTTS-WQ13645MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ6801MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DS-8201
GTTS-WQ4693MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986168
GTTS-WQ6039MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO 136
GTTS-WQ7877MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ12779MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ12027MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MM-302
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW